长链非编码RNA在骨肉瘤化疗耐药机制中的研究进展

Research Progress of Long Non-coding RNA in Mechanism of Drug Resistance in Osteosarcoma

骨肉瘤是骨科最常见的恶性肿瘤,初次确诊时往往伴有肺部转移,且耐药发生率较高。近年化疗方案的优化已经明显改善了骨肉瘤患者的预后,但化疗耐药性仍是临床医师面临的难题。长链非编码RNA(lncRNA)是骨肉瘤细胞耐药调节中的重要靶点,它从促进细胞自噬与凋亡、调控肿瘤细胞侵袭迁移、调节药物敏感性及细胞微环境等方面参与骨肉瘤细胞耐药的分子机制。因此,靶向调节lncRNA及相关信号因子水平有望改善骨肉瘤细胞的耐药性,但目前其具体分子机制尚未完全阐明,仍需要进一步探索。

Osteosarcoma is the most common malignant tumor in orthopedics,often accompanied by lung metastasis upon initial diagnosis,and has a high incidence of drug resistance.In recent years,the optimization of chemotherapy regimens has significantly improved the prognosis of the osteosarcoma patients,but chemotherapy resistance remains a challenge faced by the clinical physicians.Long non-coding RNA(lncRNA)is an important target in the regulation of drug resistance in osteosarcoma cells,which participates in the molecular mechanism of drug resistance in osteosarcoma cells by promoting autophagy and apoptosis,regulating tumor cell invasion and migration,regulating drug sensitivity and cell microenvironment.Therefore,targeted regulation of lncRNA and related signaling factors is expected to improve the drug resistance of osteosarcoma cells,but the specific molecular mechanism has not been fully elucidated,and further exploration is still needed.